# US 2015/0086591 A1 · Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0086591 A1
- Document ID: US20150086591A1
- Status: Published application
- Kind: A1
- Application number: 14/494,001
- Filed: 2014-09-23
- Published: 2015-03-26
- Earliest claimed: 2013-09-25
- Assignees: Sequoia Sciences, Inc.
- Applicants: Sequoia Sciences, Inc
- Inventors: Gary Eldridge; Steven M. Martin
- Web page: https://patentgrep.com/patent/US20150086591A1

## CPC

- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 39/0258: {Escherichia}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.

## Claims

### Claim 1

A pharmaceutical composition comprising PHAD and a buffer selected from the group consisting of citrate and succinate from 25 mM to about 50 mM.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition comprises phosphatidylcholine at a molar ratio with PHAD at about 1:1 to about 20:1, wherein phosphatidylcholine is selected from the group consisting of DMPC, DPPC, DSPC, POPC, and DOPC.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the buffer concentration is from 30 mM to about 50 mM.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the buffer concentration is from 40 mM to about 50 mM, and is at a pH of about 4.0 to about 7.5.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the buffer is citrate.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the buffer is succinate.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the composition is exposed to room temperature for 60 or more days prior to being administered to a human as an adjuvant.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the composition is stable when stored at room temperature for 6 or more months and between room temperature and about 37° C. for 2 or more months.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the composition is substantially free of a saline.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the composition contains less than 10 mM of NaCl.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the composition is essentially free of NaCl.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the composition is essentially free of cholesterol, phosphatidylglycerol, and squalene.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the composition comprises an effective amount of FimCH.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the composition has not been subjected to lyophilization.

### Claim 15

A pharmaceutical composition comprising PHAD and a buffer selected from the group consisting of sodium phosphate dibasic, sodium phosphate monobasic, potassium phosphate monobasic, and potassium phosphate dibasic from 28 mM to about 50 mM, wherein said composition is substantially free of a saline.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the composition comprises a phosphatidylcholine at a molar ratio with PHAD at about 1:1 to about 20:1, wherein phosphatidylcholine is selected from the group consisting of DMPC, DPPC, DSPC, POPC, and DOPC.

### Claim 17 (depends on 15)

The composition of claim 15, wherein the buffer concentration is from 30 mM to about 50 mM.

### Claim 18 (depends on 15)

The composition of claim 15, wherein the buffer concentration is from 40 mM to about 50 mM, at a pH of about 4.0 to about 7.5.

### Claim 19 (depends on 15)

The composition of claim 15, wherein the composition contains less than 10 mM of NaCl.

### Claim 20 (depends on 15)

The composition of claim 15, wherein the composition is essentially free of NaCl.

### Claim 21 (depends on 15)

The composition of claim 15, wherein the composition is essentially free of cholesterol, phosphatidylglycerol, and squalene.

### Claim 22 (depends on 15)

The composition of claim 15, wherein the composition comprises an effective amount of FimCH.

### Claim 23 (depends on 15)

The composition of claim 15, wherein the composition is exposed to room temperature for 60 or more days prior to being administered to a human as an adjuvant.

### Claim 24 (depends on 15)

The composition of claim 15, wherein the composition is stable when exposed to room temperature for 6 or more months and between room temperature and about 37° C. for 2 or more months.

### Claim 25 (depends on 15)

The composition of claim 15, wherein the composition has not been subjected to lyophilization.

### Claim 26

A method for administering a vaccine composition to a human comprising the step of:
administering to the human a vaccine composition comprising an adjuvant formulation containing phosphatidylcholine, about 20 μg to about 50 μg of PHAD, and a buffer selected from the group consisting of citrate and succinate from 25 mM to about 50 mM.

### Claim 27 (depends on 26)

The method of claim 26, wherein the adjuvant formulation is essentially free of cholesterol and phosphatidylglycerol.

### Claim 28

A method for treating recurrent urinary tract infections in a human comprising the step of:
administering to the human a vaccine composition comprising (i) an effective amount of FimCH, (ii) an adjuvant formulation containing phosphatidylcholine, about 20 μg to about 50 μg of PHAD, and a buffer selected from the group consisting of citrate, succinate, and phosphate from 10 mM to about 50 mM, wherein the composition is essentially free of squalene.

### Claim 29 (depends on 28)

The method of claim 28, wherein the composition is substantially free of saline.

### Claim 30 (depends on 28)

The method of claim 28, wherein the buffer is selected from the group of citrate and succinate from 25 mM to about 50 mM, at a pH of about 4.0 to about 7.5.
